Farlow, Martin R., Alva, Gus, Meng, Xiangyi, Olin, Jason T.

Objective: To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease receiving concomitant memantine. Research design and methods: Post hoc analysis of a 25-week, randomized, prospective, open-label, parallel-group study. Patients receiving donepezil were switched to rivastigmine patches (4.6 mg/24 h) immediately or following a 7-day withdrawal for 4 […]

Froelich, Lutz, Andreasen, Niels, Tsolaki, Magda, Foucher, Arnaud, Kavanagh, Shane, Van Baelen, Bart, Schwalen, Susanne

Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]

Clerici, Francesca, Vanacore, Nicola, Elia, Antonietta, Spila-Alegiani, Stefania, Pomati, Simone, Da Cas, Roberto, Raschetti, Roberto, Mariani, Claudio

Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug’s effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimer’s disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association criteria has been conducted to date. Objective: […]

Tariot, Pierre, Salloway, Steven, Yardley, Jane, Mackell, Joan, Moline, Margaret

Background: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and randomized 2:1 to either increase their donepezil dose to […]

De Deyn, Peter Paul, Eriksson, Hans, Svensson, Hanna

Objective: The objective of this study was to assess the safety and tolerability of extended-release quetiapine fumarate (quetiapine XR) compared with quetiapine immediate-release (quetiapine IR) in older patients with Alzheimer’s disease with symptoms of psychosis and/or agitation.; Methods: This was a 6-week, double-blind, double-dummy, randomised study. Of the 109 patients screened, 100 were randomised to […]

Rappaport, Stephen A., Marcus, Ronald N., Manos, George, McQuade, Robert D., Oren, Dan A.

Objectives: To evaluate the tolerability of intramuscular (IM) aripiprazole in patients with agitation associated with dementia.; Design: A 24-hour, double-blind, placebo-controlled, randomized study.; Setting: Sixteen healthcare facilities in the United States.; Participants: A total of 129 patients with acute agitation associated with Alzheimer’s, vascular or mixed dementia in healthcare facilities.; Intervention: Patients were randomized to […]

Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique

Aims: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer’s disease (AD).; Methods: Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD Cooperative Study-Activities of […]